Artificial intelligence is beginning to reshape one of oncology's more specialized frontiers: radiopharmaceuticals, the radioactive drugs used to find and destroy cancer cells.
A new feature story in the Journal of Medical Internet Research (JMIR) lays out how the technology is being applied. Written by JMIR Correspondent Benedette Cuffari, the "News and Perspectives" piece surveys recent technological advances in cancer care, according to the report reproduced by Medical Xpress.
The article's focus is twofold. First, AI is being used to accelerate radiopharmaceutical drug discovery — the process of designing new radioactive compounds that target tumors. Second, the technology is being used to optimize personalized dosimetry, meaning the careful calculation of how much radiation a specific patient should receive.
That second point matters because radiopharmaceuticals carry a delicate balance: enough radiation to attack the cancer, but not so much that it harms healthy tissue. Tailoring the dose to the individual patient, rather than relying on one-size-fits-all figures, is where AI's ability to crunch complex data could make a difference.
The coverage stops short of naming specific drugs, companies, or trial results; both source items point to the same JMIR feature summarized by Medical Xpress, and the fuller detail sits in the original journal article.
Why it matters: if AI can both shorten the years-long search for new cancer-fighting compounds and fine-tune each patient's radiation dose, it points toward treatments that are faster to develop and safer to deliver.